The Food and Drug Administration is reviewing Acadia Pharmaceuticals Inc.'s (Nasdaq: ACAD) Nuplazid, which was approved to treat hallucinations and delusions associated with Parkinson's disease. Shares of the biopharmaceutical plummeted $4.27 to close at $15.20.
FDA reviews Acadia Pharmaceuticals' Nuplazid
April 25, 2018 at 17:47 PM EDT
